Signifier Medical Technologies treats 10,000 patients with wireless, smart sleep apnea therapy
29 Mar 2023
Drug Approval
Boston-based Signifier designed eXciteOSA as a daytime therapy for sleep-disordered breathing. The company says it’s the only such treatment with FDA authorization.
The 20-minute daytime therapy allows patients to restore their nighttime breathing naturally. It comes through a wireless, smart device.
Nasdaq recognized this milestone by congratulating the company on the Nasdaq Tower in Times Square, New York.
“This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients,” said Signifier co-founder and CEO Akhil Tripathi. “It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.”
This kind of treatment could open up new avenues for patients with sleep apnea. Philips remains out of the market due to a massive recall surrounding its sleep therapy devices.
ResMed at first struggled to cope with increased orders and supply chain shortages as that recall unfolded. However, earlier this year, the company said it boosted production to alleviate the CPAP shortage. Inspire Medical, which develops an implantable sleep apnea therapy, saw a massive sales bump this year, too.
More about Signifier Medical and the eXciteOSA
The FDA authorized marketing for eXciteOSA in February 2021. Signifier’s prescription-only device is used while awake to improve tongue muscle function. This can help prevent the tongue from collapsing backward and obstructing the airway during sleep. It represents the first device of this kind for use while awake.
The smart, wireless device pairs with an intuitive app and a dedicated sleep advocate for one-on-one coaching and support.
Past studies associate the device with reductions in both objectively measured and bed-partner-reported snoring, the Signifier said. It also demonstrated significant improvements in disease severity, measured by the Epworth Sleepiness Scale, and Pittsburgh Sleep Quality Index. Clinical trial participants experienced a significant reduction in apnea-hypopnea index (AHI).
“eXciteOSA is a new and novel daytime treatment for sleep apnea. Burden of use is as low as 20 minutes.” Evidence is mounting about the positive effects of eXciteOSA in improving disease severity and daytime sleepiness. Patients now have an alternative approach that is easy to use and well accepted,” said Dr. Naresh M. Punjabi, chief, division of pulmonary, critical care, and sleep medicine at the University of Miami.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.